Forest plots of secondary outcomes after negative pressure wound therapy versus conventional wound care for sternal wound infection. by Si He (3236646)

Subjects:

Study flow chart. by Karl Ingard (22582091)

Subjects:

Extracted data and used for analysis. by Si He (3236646)

Subjects:

Kaplan-Meier curve of the primary outcome. by Karl Ingard (22582091)

Subjects:

Number of Patients Who Reached the Primary and Secondary Endpoints During Follow-up. by Karl Ingard (22582091)

Subjects:

Excluded studies with reasons for exclusion. by Si He (3236646)

Subjects:

Subgroup Analysis of the Occurrence of the Primary Endpoint and Its Components. by Karl Ingard (22582091)

Subjects:

Flow diagram of the studies included in the meta-analysis. by Si He (3236646)

Subjects:

Vertebral cancellous tissueμCT parameters are not significantly affected by aging from 16 to 21 weeks, housing type, or microgravity. by Rukmani Cahill (20939813)

“…Nonsignificant trends implicate an effect of spaceflight reducing BV/TV, increasing DA, and reducing Tb.N. Data shown are the mean ±  standard deviation with a scatter plot (ns: non-significant). …”

Effect of Oxamate, LBP, or their combination on partial glycolysis metabolites in A549 and NCL-H1975 cells after 24 hours of treatment. by Siyu Yuan (7425719)

Subjects:

Cinnamaldehyde repellency test within 6 hours in parthenogenesis <i>H. longicornis.</i> by Ceyan Kuang (8554557)

Subjects:

Supplementing NAD+ counters the effects of Oxamate on metabolism and chemotherapy sensitivity. by Siyu Yuan (7425719)

Subjects:

Shares of antibiotic substances on total prescription in UTI treatment (N39.0, N30.0) by sex and age group in 2019 (female: n = 238.670 prescriptions; male: n = 40.641 prescription... by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Shares of antibiotic substances on total prescription by quarter from 2013 to 2019 for female and male patients with UTI (N39.0, N30.0)(female: n = 1.681.255 prescriptions; male: n... by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Shares of specialist groups prescribing 1^st, 2^nd, and 3^rd antibiotic prescriptions in UTI treatment of females (N39.0, N30.0) in 2018 and 2019. by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Number of antibiotic prescriptions in female and male patients with UTI (N30.0 and/or N39.0). by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Shares of antibiotic substances on total prescription in female patients with UTI (N39.0, N30.0) by physician specialties (GPs: n = 1.299.641 prescriptions; gynecologists n = 141.8... by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Comparison of 1^st, 2^nd, and 3^rd antibiotic prescription. by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

UTI diagnoses by sex and physician specialty (2013–2019). by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Oxamate reduces cell viability, LDHA expression, and LDH activity in A549 and NCL-H1975 cells, enhancing the cytotoxic effect of LBP. by Siyu Yuan (7425719)

Subjects: